Yani Arhab | Viral Strategies | Best Researcher Award

Posted on 20/11/202421/11/2024 by PencisLeave a Comment

Dr. Yani Arhab | Viral Strategies | Best Researcher Award

SUNY Downstate Health Sciences University | United States

Author Profile

Scopus

Orcid ID

Google Scholar

YANI ARHAB, PHD 🎓🔬

EARLY ACADEMIC PURSUITS 📚

Yani Arhab’s academic journey began at the University François Rabelais of Tours (France), where he earned his BSc in Biology. During his studies, he participated in an Erasmus program, studying at Queen Mary University of London. He continued his education at University Claude Bernard Lyon1, completing his Master's in Structural & Functional Biochemistry. Yani further honed his skills during a Master’s 2 training at the ICBMS, where he worked on the structural and functional characterization of phospholipases D in plants.

PROFESSIONAL ENDEAVORS 💼

Yani's career spans multiple prestigious institutions and roles. From 2015 to 2018, he earned his PhD at the University of Lyon, where he focused on phospholipases D, under the guidance of Pr. A. Abousalham and Dr. A. Noiriel. Following this, he served as a full-time associate professor at Université Claude Bernard Lyon1 in 2018-2019. Since 2019, Yani has been a Postdoctoral Associate at the State University of New York, Downstate Medical Center, where he is studying the reconstitution of ribosomal initiation complexes on viral RNA Internal Ribosome Entry Sites (IRES) under the mentorship of Dr. Christopher Hellen and Dr. Tatyana Pestova.

CONTRIBUTIONS AND RESEARCH FOCUS ON VIRAL STRATEGIES🧬

Yani’s research focuses on biochemistry, particularly in the areas of ribosomal initiation, lipid biochemistry, and the structural and functional analysis of enzymes. His work on phospholipases D has contributed significantly to understanding lipid metabolism and its impact on cellular functions. In his current research, he is studying viral RNA IRES and their mechanisms in translation initiation, which has important implications for viral infections and potential therapeutic targets.

IMPACT AND INFLUENCE 🌍

Yani’s work is influencing multiple fields of molecular biology and biochemistry, particularly through his contributions to understanding the molecular mechanisms behind viral translation and enzyme function. His research on IRES mechanisms is helping expand our knowledge of viral RNA translation, with the potential to influence future antiviral strategies.

ACADEMIC CITATIONS 📈

Throughout his academic career, Yani Arhab has gained recognition for his innovative research, presenting his findings at international conferences such as the Translational Control Symposium at Cold Spring Harbor Laboratory and the Ribosome Structure & Function Conference. His research contributions have resulted in numerous publications and are frequently cited by peers in the fields of biochemistry, molecular biology, and virology.

LEGACY AND FUTURE CONTRIBUTIONS 🔮

Yani Arhab’s legacy is defined by his commitment to advancing our understanding of molecular biology. He has built a solid foundation of research that will continue to shape the future of biochemical research, particularly in the fields of RNA biology and viral research. Looking ahead, he plans to further investigate the complex interactions of ribosomal initiation and their implications for therapeutic development, particularly for viral diseases.

AWARDS AND SCHOLARSHIPS 🏆

2015, 2016, 2018: Research funds from the Ligue National Contre le Cancer (€15,000)
2017: FEBS+3 travel grant (€750)
2015: Ph.D. bursary recipient

PROFESSIONAL MEMBERSHIPS 🤝

Member of the AFC (French Crystallography Society)
Member of the SFBBM (French Molecular Biology and Biochemistry Society)
Associate Professor in Biochemistry and Molecular Biology since 2019

TEACHING EXPERIENCE 🍎

Yani Arhab has contributed to the education of future scientists by teaching both lectures and experimental courses in biochemistry. He has mentored undergraduate students in subjects such as protein purification, lipid characterization, and enzymatic assays, fostering the next generation of researchers. Yani Arhab's work exemplifies the intersection of molecular research and practical application in medicine, showcasing his contributions to both academia and the scientific community at large.

NOTABLE PUBLICATIONS 📑

"Heterologous expression, kinetic characterization and molecular modeling of a new sn-1,3-regioselective triacylglycerol lipase from Serratia sp. W3"

Authors: Eddehech, A. , Rahier, R. , Smichi, N. , Sayari, A. , Zarai, Z.
Journal: Process Biochemistry
Year: 2021

"Phospholipase D inhibitors screening: Probing and evaluation of ancient and novel molecules"

Authors: Arhab, Y. , Bessaa, K. , Abla, H. , Abousalham, A. , Noiriel, A
Journal: International Journal of Biological Macromolecules
Year: 2021

"Corrigendum to “Production, purification and functional characterization of phospholipase C from Bacillus thuringiensis with high catalytic activity”

Authors: Eddehech, A. , Smichi, N. , Arhab, Y. , Gargouri, Y. , Zarai, Z.
Journal: Process Biochemistry
Year: 2019

"Production, purification and functional characterization of phospholipase C from Bacillus thuringiensis with high catalytic activity"

Authors: Eddehech, A. , Smichi, N. , Arhab, Y. , Gargouri, Y. , Zarai, Z.
Journal: Process Biochemistry
Year: 2019

"Plant phospholipase D mining unravels new conserved residues important for catalytic activity"

Authors: Arhab, Y. , Abousalham, A. , Noiriel, A.
Journal: Molecular and Cell Biology of Lipids
Year: 2019

Ralph Scully | Homologous Recombination | Best Researcher Award

Posted on 20/11/202420/11/2024 by PencisLeave a Comment

Dr. Ralph Scully | Homologous Recombination | Best Researcher Award

Harvard Medical School | United States

Author Profile

Scopus

Google Scholar

RALPH SCULLY: PIONEER IN GENOMIC STABILITY AND DNA REPAIR 🧬

Dr. Ralph Scully is a globally recognized leader in cancer biology, genomic stability, and DNA repair mechanisms. His illustrious academic career spans decades, marked by groundbreaking research and influential leadership in the biomedical sciences.

EARLY ACADEMIC PURSUITS 🎓

Dr. Scully began his academic journey with a B.A. (Hons) in Medical Sciences and English from the University of Cambridge in 1983, followed by an M.B., B.S. in Clinical Sciences from University College London in 1986. He later earned an M.A. in Medical Sciences and English in 1990 and culminated his academic studies with a Ph.D. in Immunology under the mentorship of Herman Waldmann, F.R.S., at Cambridge in 1994. This interdisciplinary foundation laid the groundwork for his innovative approach to medical research.

PROFESSIONAL ENDEAVORS 🏥

Dr. Scully’s professional trajectory showcases his dedication to both clinical and academic excellence:

Postdoctoral Training (1994-1997): Focused on neoplastic disease mechanisms at the Dana-Farber Cancer Institute under Dr. David M. Livingston.
Harvard Medical School Faculty: Starting as an Instructor in 1997, he progressed through the ranks to become a Professor of Medicine in 2017. He has also served as faculty for the Ph.D. Program in Biological and Biomedical Sciences.
Administrative Leadership: Co-Director of the Program in DNA Repair and Genomic Instability at Beth Israel Deaconess Medical Center since 2018.

CONTRIBUTIONS AND RESEARCH FOCUS ON HOMOLOGOUS RECOMBINATION🔬

Dr. Scully's research explores the molecular mechanisms of DNA repair, genomic instability, and cancer biology, particularly in relation to BRCA genes. His work has illuminated pathways critical to understanding cancer development and therapy resistance. Highlights include:

Leading efforts in understanding genomic rearrangements and mutational signatures in cancer.
Driving advancements in genome editing technologies and their implications for cancer prevention and treatment.
Collaborative projects on BRCA-linked cancer prevention, including international coalitions.

IMPACT AND INFLUENCE 🌍

Dr. Scully has profoundly influenced the field through:

Organizing major scientific conferences such as the Keystone Symposium on Genomic Instability and DNA Repair (2023) and the FASEB Conference on Genetic Recombination (2026, 2028).
Serving as a chair and advisory member for numerous academic committees, fostering collaborations across global institutions.
His mentorship of emerging scientists, equipping the next generation with critical insights into genomic medicine.

ACADEMIC CITATIONS AND RECOGNITION 📚

Dr. Scully's publications are extensively cited, reflecting the high impact of his research in genomics and cancer biology. As a thought leader, he has contributed to the editorial boards and review committees of prestigious journals and funding agencies, ensuring the dissemination of transformative research.

LEGACY AND FUTURE CONTRIBUTIONS 🌟

Dr. Scully’s ongoing commitment to tackling genomic instability has positioned him as a pioneer whose work continues to inform cancer prevention and treatment strategies. His leadership in upcoming conferences and collaborative projects signifies a lasting legacy in the biomedical field.

OTHER NOTABLE ACHIEVEMENTS 🏅

Professional Societies: Member of esteemed organizations such as the American Association for Cancer Research and the Association of American Physicians.
Consultancy Roles: Provided expert guidance to biotech companies like Editas, Cyteir, and MoMa Therapeutics.
Grant Reviews and Committees: Regularly contributes to panels for the NIH, ACS, and Charles A. King Trust Fellowship Program.

NOTABLE PUBLICATIONS 📑

"One-ended and two-ended breaks at nickase-broken replication forks"

Authors: Scully, R. , Walter, J.C. , Nussenzweig, A.
Journal: DNA Repair
Year: 2024

"Exploiting CRISPR/Cas9 to engineer precise segmental deletions in mouse embryonic stem cells"

Authors: Elango, R. , Panday, A. , Willis, N.A. , Scully, R.
Journal: STAR Protocols
Year: 2022

"A modified CUT&RUN-seq technique for qPCR analysis of chromatin-protein interactions"

Authors: Panday, A. , Elango, R. , Willis, N.A. , Scully, R.
Journal: STAR Protocols
Year: 2022

"The structure-specific endonuclease complex SLX4–XPF regulates Tus–Ter-induced homologous recombination"

Authors: Elango, R. , Panday, A. , Lach, F.P. , Smogorzewska, A. , Scully, R.
Journal: Nature Structural and Molecular Biology
Year: 2022

"Recombination and restart at blocked replication forks "

Authors: Scully, R. , Elango, R. , Panday, A. , Willis, N.A.
Journal: Current Opinion in Genetics and Development
Year: 2021

Sami Nassar | Cancer Genetics and Genomics | Best Researcher Award

Posted on 26/09/202405/10/2024 by PencisLeave a Comment

Dr. Sami Nassar | Cancer Genetics and Genomics | Best Researcher Award

Medical University of South Carolina | United States

Author Profile

Orcid ID

🌟 SAMI I. NASSAR: A DEDICATED JOURNEY IN MEDICINE AND RESEARCH

EARLY ACADEMIC PURSUITS 🎓

Sami I. Nassar began his academic journey at Columbia University, where he majored in Neuroscience and Behavior, graduating Cum Laude in 2019 with an impressive GPA of 3.94/4.00. His academic excellence earned him a place in the Psi Chi International Honor Society in Psychology for his outstanding achievements. This strong foundation in neuroscience laid the groundwork for his future medical career. He is currently pursuing his MD at Wayne State University, School of Medicine, where he is on track to graduate in June 2024, having achieved a Step 2 Score of 258—a testament to his dedication to medical excellence.

PROFESSIONAL ENDEAVORS 👨‍⚕️

Throughout his career, Nassar has actively engaged in clinical and research positions across prestigious institutions. His experience as a Research Fellow at the Medical University of South Carolina since 2024 has enabled him to delve into otolaryngological topics, including vertiginous disorders and suicide risk in head and neck cancer patients. At the Henry Ford Health System and Karmanos Cancer Institute, he contributed to significant research on molecular biomarkers and substance use among cancer patients, helping to push the boundaries of cancer research and patient care. His earlier roles, including work at Generation Next Fertility and Columbia University, demonstrate his practical skills in clinical and laboratory settings, offering a holistic approach to patient care and research. These roles also gave him experience in collaborating with medical professionals and managing clinical trials, which have been integral to his development as a medical researcher.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS AND GENOMICS 🔬

Nassar’s research has focused heavily on otolaryngology, head and neck cancer, and HPV-related carcinomas. His work on identifying molecular biomarkers and risk factors in cancer patients, such as those for suicide and substance use, has been groundbreaking. His research not only seeks to understand the molecular foundations of cancer but also aims to improve the quality of life for cancer patients. His investigations into tinnitus and vertiginous disorders add further depth to his research portfolio, contributing to patient outcomes in the field of ear, nose, and throat (ENT) medicine.

IMPACT AND INFLUENCE 🏆

Nassar's research has been widely recognized within the medical community, as seen through numerous awards. His work has been presented at leading conferences, such as the American Head and Neck Society's 11th International Conference, where he won the 3rd place poster award in the Education/Care Delivery category. His earlier recognition by the American Journal of Gastroenterology in 2021 further highlights his ability to contribute to diverse fields of medicine. His influence extends to peer-reviewed academic journals, where his manuscripts and abstracts have garnered attention, solidifying his reputation as a promising researcher.

ACADEMIC CITES 📚

Nassar’s work has been cited in reputable journals, including Cancer Epidemiology, Biomarkers & Prevention, and the American Journal of Gastroenterology. His published work on topics like teduglutide therapy for Short Bowel Syndrome and cancer epidemiology reflects his ability to contribute to high-impact scientific literature. These citations, alongside his ongoing manuscripts on suicide and substance use in cancer patients, illustrate his influence on ongoing medical research.

LEGACY AND FUTURE CONTRIBUTIONS 🌍

As a young and promising researcher, Nassar is poised to make even more significant contributions to the field of medicine. His research on biomarkers and immunochemotherapy for cancer treatment, as well as his ongoing investigation into the psychological aspects of cancer care, will likely have a lasting impact on both academic research and clinical practice. His focus on improving patient quality of life through research on mental health and substance use demonstrates his commitment to a holistic approach to medicine, one that integrates both physical and mental health outcomes. His legacy will undoubtedly include shaping future practices in otolaryngology, head and neck oncology, and biomolecular cancer therapy. With his continued drive and dedication, Nassar’s future contributions to medical science promise to push boundaries and pave the way for innovative treatments and care models.

NOTABLE PUBLICATIONS 📑

"S3030 Safety and Efficacy of Teduglutide Therapy for Management of Short Bowel Syndrome After Intestinal Transplantation"

Authors: Sami I. Nassar; Syed-Mohammed Jafri
Journal: American Journal of Gastroenterology
Year: 2021

"Abstract C067: Disparities in health literacy in patients with head and neck cancer: Considerations for understanding"

Authors: Aleksandra Vidovich; Amy Williams; Samantha H. Tam; Mary K. Miller; Maria Olex; Sami Nassar; Alex Rodriguez; Eric Adjei Boakye
Journal: Cancer Epidemiology, Biomarkers & Prevention
Year: 2023

"The Role of ctDNA and Liquid Biopsy in the Diagnosis and Monitoring of Head and Neck Cancer: Towards Precision Medicine"

Authors: Sami I. Nassar; Amber Suk; Shaun A. Nguyen, MD; Dauren Adilbay; John Pang; Cherie-Ann Nathan
Journal: Cancer
Year: 2024

Gang liu | Cancer | Best Researcher Award

Posted on 05/09/202405/09/2024 by PencisLeave a Comment

Prof Gang liu | Cancer | Best Researcher Award

Gansu Provincial Center for Disease Control and Prevention | China

Author Profile

Scopus

Gang Liu: Pioneer in Radiobiology and Preventive Medicine ⚛️

EARLY ACADEMIC PURSUITS 🎓

Gang Liu began his academic journey at Lanzhou University, where he pursued a PhD in preventive medicine. His graduation in 1997 marked the beginning of a career dedicated to understanding the impacts of radiation on health. His academic training in preventive medicine provided the foundation for his future contributions to radiobiology and public health, particularly in the context of disease control and prevention.

PROFESSIONAL ENDEAVORS 🏢

After obtaining his PhD, Gang Liu embarked on a distinguished career at the Gansu Provincial Center for Disease Control and Prevention. His professional focus has been on the intersection of radiobiology, immunology, and tumor screening. In 2019, his registration as a health physicist signaled a significant milestone. He became the technical lead for a groundbreaking study on low-dose dose-effect relationships, a critical area in radiation therapy and safety. His expertise in radiation protection and therapy has earned him a prominent position within the medical research community.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER🧬

Gang Liu's research primarily revolves around radiobiology and radiation protection in therapy. His technological advancements in biological dose estimation are considered cutting-edge within China and recognized internationally. One of his significant contributions was revising the 2011 IAEA Manual based on findings from his studies on radiological sensitivity and dose rates. This revision, coupled with his publications in the FASEB Journal, has made Liu a leading figure in radiation science. His work in chromosomal aberration analysis and developing noninvasive techniques for early-stage cancer screening underscores his innovative approach to medical research.

IMPACT AND INFLUENCE 🌍

Gang Liu's influence extends beyond national borders. His research on radiological sensitivity and dose rates, especially in the context of cancer screening and radiation therapy, has set new benchmarks in the field. The international recognition of his work, particularly his advancements in biological dose estimation and contributions to global radiation protection protocols, underscores his importance in radiobiology. His work is used by institutions worldwide to improve radiation safety standards and enhance cancer diagnostic techniques.

ACADEMIC CITATIONS 📚

His pioneering research has been published in prestigious journals such as the FASEB Journal, one of the top international platforms for scientific contributions. The citations of his work in radiological sensitivity, chromosomal aberration analysis, and cancer screening techniques reflect his deep impact on the scientific community, with his methods influencing both practical applications in healthcare and further research.

LEGACY AND FUTURE CONTRIBUTIONS 🔬

Gang Liu’s legacy will likely be defined by his leadership in advancing radiation protection technology and cancer screening techniques. As an innovator in radiological health, his influence will continue to grow through future contributions to radiation therapy safety, noninvasive cancer detection, and international health standards. His ongoing work in exploring new methods for biological dose estimation will further establish his standing as a key figure in the evolution of radiation medicine.

NOTABLE PUBLICATIONS 📑

"Study of Low-Dose Radiation Workers Ionizing Radiation Sensitivity Index and Radiation Dose-Effect Relationship"

Authors: Liu, G., Zhang, R., Li, Y., Liu, Y.Y., Zhang, X.
Journal: Health Physics
Year: 2022

"Revision of cytogenetic dosimetry in the IAEA manual 2011 based on data about radio-sensitivity and dose-rate findings contributing"

Authors:Liu, G.
Journal: FASEB Journal
Year: 2022

"Thyroid dose assessments due to inhalation of 131I for nuclear medicine workers"

Authors: Liu, G., Li, Y., Zhang, H., Niu, L.M., Zhang, R.
Journal: Frontiers in Public Health
Year: 2022

"Study of Indicators for Early and Rapid Diagnosis of Radiation Injury Is the Most Important in Patients With Cancer During Radiotherapy"

Authors: Liu, G., Niu, L.-M., Wang, L.-Q., Liu, Y.-Y., Zhang, R.
Journal: Dose-Response
Year: 2020

"Chromosomal aberration analysis: Novel noninvasive techniques for early-stage cancer screening"

Authors: Liu, G.
Journal: Clinica Chimica Acta
Year: 2024

Bruno Fuchs | Sarcoma | Excellence in Innovation

Posted on 22/08/202422/08/2024 by PencisLeave a Comment

Prof Dr. Bruno Fuchs | Sarcoma | Excellence in Innovation

Swiss Sacroma Network | Switzerland

Author Profile

Orcid ID

Bruno Fuchs, MD, PhD 🌟

Position: Professor and Chair, Sarcoma Center & Swiss Sarcoma Network

Location: Faculty of Health Science & Medicine, University of Lucerne, and LUKS University Hospital, Luzern, Switzerland

Contact: fuchs@sarcoma.surgery

Educational Background 🎓

2022: Guest-Professor, Medical Faculty, University of Lucerne
2010: Extraordinarius, Medical Faculty, University of Zurich
2005: Associate Professor, Medical Faculty, University of Zurich
2004: PhD in Biomedical Sciences (Tumor Biology), Mayo Graduate School, Mayo College of Medicine, Rochester, MN, USA
1996 - 2004: Training and Fellowship in Orthopedic Surgery and Musculoskeletal Oncology at Mayo Clinic, Rochester, MN, USA, and Swiss institutions
1992: MD, Medical Faculty, University of Zurich, Switzerland

Clinical and Research Expertise 🔬

Specializes in the surgical treatment of bone and soft tissue tumors in both pediatric and adult patients
Focuses on outcome analysis and quality indicators in sarcoma care
Engages in predictive outcome analytics for improving sarcoma treatment

Academic Contributions 📚

Authored over 200 publications and book chapters
Acquired over 10 million Swiss Francs in research funding
Active as a reviewer for prestigious journals and grant committees

Contributions and Research Focus on Sarcoma🏆

Fuchs has made profound contributions to the surgical treatment of bone and soft tissue tumors in both pediatric and adult patients. His research is heavily focused on the outcome analysis of sarcoma patients, defining and assessing quality indicators of sarcoma care, and predictive outcome analytics. His work is vital in improving the standards and methodologies employed in sarcoma care, directly impacting patient outcomes and care quality.

Public and Professional Service 🌐

Founder & Chair of the Swiss Sarcoma Network
Founder of the Sarcoma Academy
Member of multiple medical societies including SwissOrthopaedics, FMH, and CTOS

Dr. Bruno Fuchs is recognized internationally for his extensive contributions to the field of sarcoma research and treatment. His work continues to shape the future of musculoskeletal oncology.

Notable Publications📑

"Real-World-Time Data and RCT Synergy: Advancing Personalized Medicine and Sarcoma Care through Digital Innovation"

Authors: Philip Heesen, Georg Schelling, Mirko Birbaumer, Ruben Jäger, Beata Bode, Gabriela Studer, Bruno Fuchs
Journal: Cancers
Year: 2024

"Improving Sarcoma Outcomes: Target Trial Emulation to Compare the Impact of Unplanned and Planned Resections on the Outcome"

Authors: Timothy T. A. F. Obergfell, Kim N. Nydegger, Philip Heesen, Georg Schelling, Beata Bode-Lesniewska, Gabriela Studer, Bruno Fuchs
Journal: Cancers
Year: 2024

"Impact of Institutional Practices and Surgical Complexity on Sarcoma Surgery Costs: Driving Efficiency in Value-Based Healthcare"

Authors: Georg Schelling, Philip Heesen, Boris Malte Tautermann, Markus Wepf, Barbara Di Federico, Annika Frei, Kim van Oudenaarde, Pietro Giovanoli, Beata Bode-Lesniewska, Gabriela Studer et al.
Journal: Cancers
Year: 2024

"Development and Validation of the Bone Tumor Surgery Complexity Score"

Authors: Annika Frei, Georg Schelling, Philip Heesen, Pietro Giovanoli, Bruno Fuchs
Journal: Reports
Year: 2024

"Exploring Risk Factors for Predicting 30-Day Postoperative Morbidity in Musculoskeletal Tumor Surgery"

Authors: Philip Heesen, Maria Elyes, Jan Domanski, Georg Schelling, Sören Könneker, Bruno Fuchs
Journal: Journal of Clinical Medicine
Year: 2024

Bin Zhang | Gene Mutation | Best Researcher Award

Posted on 26/05/202426/05/2024 by PencisLeave a Comment

Prof Bin Zhang | Gene Mutation | Best Researcher Award

Jining Medical University | China

AUTHOR PROFILE

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Bin Zhang's journey into the world of medical research began with a solid foundation in biomedical sciences. His early academic pursuits were marked by a dedication to understanding complex biological systems and a passion for contributing to the field of oncology. This academic dedication led him to become a young expert recognized under the prestigious Taishan Mount Scholars program in China.

PROFESSIONAL ENDEAVORS

In 2018, Bin Zhang was appointed as a researcher at the Affiliated Hospital of Jining Medical University. Here, he established the tumor metabolism research group, assuming the role of Principal Investigator. Under his leadership, the group has grown to focus on four key research directions: the regulatory mechanisms of tumor stem cells, the specificity of tumor biomacromolecules and energy metabolism, the regulation of energy metabolism by oncogenic gene mutations, and the screening of potential drugs targeting tumor metabolism.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE MUTATION

Bin Zhang's research has significantly advanced the understanding of tumor metabolism. His work has been published in esteemed journals such as Cell Reports Medicine, Biomaterials, Oncogene, Journal of Experimental & Clinical Cancer Research, and Stem Cells. These publications highlight his team's investigations into the intricate mechanisms of tumor biology and potential therapeutic targets. The research group delves into how tumor stem cells are regulated, how tumor biomacromolecules function, and how mutations in oncogenes affect energy metabolism, all of which are crucial for developing new cancer treatments.

IMPACT AND INFLUENCE

The impact of Bin Zhang's research is reflected in the high citation rate of his publications, with over 5000 citations to date and an H-Index of 34. His work has not only contributed valuable knowledge to the scientific community but has also influenced ongoing research and development in tumor metabolism. Furthermore, Bin Zhang has successfully secured ten patents, two of which have been transferred, demonstrating the practical applications and commercial potential of his research findings.

ACADEMIC CITES

Bin Zhang is also an active member of the academic community, serving as a reviewer for several high-impact journals including Stem Cells and Development, EBioMedicine, Stem Cell Research & Therapy, Molecular Carcinogenesis, and the Journal of Clinical Laboratory Medicine. His expertise is sought after in evaluating cutting-edge research and ensuring the quality of publications in these journals.

LEGACY AND FUTURE CONTRIBUTIONS

Bin Zhang's legacy in the field of tumor metabolism is marked by his innovative research and commitment to advancing cancer treatment. Currently, he is the principal investigator of two general projects funded by the National Natural Science Foundation of China, two projects funded by Shandong Province, and two projects funded by the Postdoctoral Foundation of China. His ongoing work promises to uncover new insights and develop novel therapies, continuing to push the boundaries of cancer research

NOTABLE PUBLICATIONS

A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis 2023(7)

IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53 2023(4)

Therapeutic Efficacy of Mesenchymal Stem/Stromal Cell Small Extracellular Vesicles in Alleviating Arthritic Progression by Restoring Macrophage Balance 2023(1)

Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines 2024

Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling 2024